Name
What's in it, and how does it get there?
NAD+ is nicotinamide adenine dinucleotide, a coenzyme that helps cells carry out chemical reactions. This coenzyme isn't part of the peptide family. NMN and NR are precursors, ingredients the body can use to make NAD+.
Intravenous means into a vein. Subcutaneous means under the skin; intramuscular means into muscle. Results from one route don't automatically apply to another. Neither do oral precursor findings.
An injection can sound more direct. That's a description of the route, though, rather than evidence that it improves health.
How does compounding change the question?
A compounded medicine is prepared by a licensed pharmacist, licensed physician or FDA-registered outsourcing facility, rather than supplied as an approved finished drug. These preparations aren't FDA-approved. The agency doesn't review their safety, effectiveness or quality before they're marketed.
A prescriber's decision doesn't give a preparation FDA approval. A prescription also doesn't remove the rules about which ingredients may be used in compounding. Provider review and ingredient eligibility are separate questions.
Measurement
What have infusion studies found?
A six-hour NAD+ infusion pilot in healthy men found no detectable rise in plasma NAD+ during the first two hours. It rose later, and researchers also recorded changes in substances passed in urine as NAD+ was processed.
Plasma is the fluid part of blood. This study helps describe how the body handles an infusion. It doesn't establish an anti-aging benefit or show delivery into every tissue.
A small comparison of intravenous NAD+ and NR looked back at existing treatment records. It reported moderate-to-severe gut symptoms, elevated heart rate and chest pressure with NAD+, compared with mild tingling with NR.
NAD+ infusions took 97 minutes on average; NR infusions took 37. Both the ingredient and the infusion time differed, so this can't tell us what infusion speed alone caused. It's a small, backward-looking study, rather than a firm verdict on either treatment.
Preparation quality is a separate safety question
FDA's explanation of compounding risks covers contamination and too much or too little active ingredient. Knowing the molecule's name can't establish how well a particular medicine was prepared.
A compounded injectable NAD+ preparation has also been recalled for elevated bacterial endotoxin, a bacterial contaminant. That concerns a specific preparation. It doesn't describe the quality of every NAD+ preparation.
Published information on under-skin and intramuscular NAD+ is especially limited. The small infusion studies can't fill that gap, or settle long-term safety.
Claim
A provider reviews the person
At Promise Peptides, a request for compounded NAD+ goes to a licensed U.S. provider for review and a prescription decision. A review can end without a prescription, and the service is for U.S. patients only. Access doesn't establish a health benefit.
Location matters in telehealth too. HHS explains that professionals need the appropriate licence or permission where the patient is located, as well as meeting requirements where they practise. A general description of U.S. care doesn't establish availability in every state.
Questions worth bringing to the conversation
What outcome is the provider considering? What evidence supports this ingredient and route? Who is responsible for preparing this particular medicine? What would make the provider decline treatment?
Those are ordinary questions, and useful ones. The study amounts page keeps research quantities in context. A care decision needs more information than the name at the top of an offer.
